Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin

JAMA Dermatol. 2018 Jan 1;154(1):109-110. doi: 10.1001/jamadermatol.2017.3961.

Authors

Connie Zhang¹, Manasmon Chairatchaneeboon², Paul Haun³, Daniel Landsburg⁴, Ellen J Kim³

Affiliations

¹ Division of Dermatology, University of Calgary, Calgary, Alberta, Canada.
² Department of Dermatology, Mahidol University, Bangkok, Thailand.
³ Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia.
⁴ Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia.

PMID: 29167875
DOI: 10.1001/jamadermatol.2017.3961

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use*
Brentuximab Vedotin
Follow-Up Studies
Humans
Immunoconjugates / therapeutic use*
Infusions, Intravenous
Ki-1 Antigen / immunology
Male
Middle Aged
Mycosis Fungoides / diagnosis
Mycosis Fungoides / drug therapy*
Mycosis Fungoides / immunology
Severity of Illness Index
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Treatment Outcome

Substances

Antineoplastic Agents
Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin